{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T18:47:12Z","timestamp":1757702832730},"reference-count":27,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2016,5,30]],"date-time":"2016-05-30T00:00:00Z","timestamp":1464566400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"National Health and Medical Research Council Senior Research Fellowship","award":["1061041"],"award-info":[{"award-number":["1061041"]}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Drug and Alcohol Review"],"published-print":{"date-parts":[[2017,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Introduction and Aims<\/jats:title><jats:p><jats:italic>Drug induced QT prolongation occurs in patients with substance use disorders from prescription medications that prolong the QT, such as methadone. Knowing the prevalence of QT prolongation in this population is important for prescribers. This study aimed to investigate the prevalence of QT prolongation in patients with current substance use disorders.<\/jats:italic><\/jats:p><\/jats:sec><jats:sec><jats:title>Design and Methods<\/jats:title><jats:p><jats:italic>We undertook a retrospective review of electrocardiograms (ECG) from patients with substance use disorders from an urban general hospital with a large drug and alcohol service and toxicology unit. ECGs were taken from patients seen by the alcohol and drug unit over three years. The QT interval was measured manually on each ECG and defined as abnormal if above the line on the QT nomogram. The QT was also heart rate corrected using Fridericia's formula (QTcF) to investigate associated factors.<\/jats:italic><\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p><jats:italic>Nine of 446 (2.0%; 95% confidence interval 1.0\u20133.9%) patients had an ECG with a prolonged QT interval. Three were prescribed methadone for opiate dependence (80, 90 and 125\u2009mg daily), one also with hypokalemia; one prescribed escitalopram with hypokalaemia\/hypomagnesaemia; three more with hypokalaemia alone. Only two patients had a prolonged QT with no identifiable cause. There was no association between QTcF and sex<\/jats:italic> (<jats:italic>P\u2009=\u20090.34), but there was a statistically significant association with age (Pearson R\u2009=\u20090.19, 95% confidence interval 0.10\u20130.28,<\/jats:italic> <jats:italic>P\u2009&lt;\u20090.0001).<\/jats:italic><\/jats:p><\/jats:sec><jats:sec><jats:title><jats:italic>Discussion and Conclusions<\/jats:italic><\/jats:title><jats:p><jats:italic>QT prolongation is rare in patients with substance use disorders and is most likely similar to the general population once cases related to methadone use and electrolyte abnormalities are excluded.<\/jats:italic> [Scott AJ, Dunlop AJ, Brown A, Craig S. The prevalence of QT prolongation in a population of patients with substance use disorders. <jats:italic>Drug Alcohol Rev<\/jats:italic> 2017;36:239\u2010244]<\/jats:p><\/jats:sec>","DOI":"10.1111\/dar.12415","type":"journal-article","created":{"date-parts":[[2016,5,31]],"date-time":"2016-05-31T04:12:58Z","timestamp":1464667978000},"page":"239-244","update-policy":"http:\/\/dx.doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["The prevalence of QT prolongation in a population of patients with substance use disorders"],"prefix":"10.1111","volume":"36","author":[{"given":"Alexander J.","family":"Scott","sequence":"first","affiliation":[{"name":"School of Medicine and Public Health University of Newcastle  Newcastle Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adrian J.","family":"Dunlop","sequence":"additional","affiliation":[{"name":"School of Medicine and Public Health University of Newcastle  Newcastle Australia"},{"name":"Drug and Alcohol Clinical Services Hunter New England Local Health District  Newcastle Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amanda","family":"Brown","sequence":"additional","affiliation":[{"name":"Drug and Alcohol Clinical Services Hunter New England Local Health District  Newcastle Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Craig","family":"Sadler","sequence":"additional","affiliation":[{"name":"School of Medicine and Public Health University of Newcastle  Newcastle Australia"},{"name":"Alcohol and Drug Unit Calvary Mater Newcastle  Newcastle Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Geoffrey K.","family":"Isbister","sequence":"additional","affiliation":[{"name":"School of Medicine and Public Health University of Newcastle  Newcastle Australia"},{"name":"Department of Clinical Toxicology and Pharmacology Calvary Mater Newcastle  Newcastle Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2016,5,30]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12040"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2001.03927.x"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra032426"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1097\/FJC.0b013e3182135e91"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.2165\/11599960-000000000-00000"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.18773\/austprescr.2015.003"},{"key":"e_1_2_7_8_1","unstructured":"National Opioid Pharmacotherapy Statistics 2014. In:Government A editor. Australian Institute of Health and Welfare. Canberra2015."},{"key":"e_1_2_7_9_1","article-title":"Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence","volume":"3","author":"Mattick RP","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-150-6-200903170-00103"},{"key":"e_1_2_7_11_1","first-page":"210","article-title":"Methadone\u2010induced mortality in the treatment of chronic pain: role of QT prolongation","volume":"16","author":"Andrews CM","year":"2009","journal-title":"Cardiol J"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annemergmed.2005.07.003"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annemergmed.2010.05.037"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12272"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annemergmed.2015.03.016"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1465-3362.2010.00213.x"},{"key":"e_1_2_7_17_1","article-title":"Methamphetamine\u2010associated QTc prolongation in a dose\u2010dependent and reversible manner","volume":"25","author":"Liang CS","year":"2013","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(93)90879-L"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1445-5994.2011.02447.x"},{"key":"e_1_2_7_20_1","first-page":"198","article-title":"Methamphetamine abuse and emergency department utilization","volume":"170","author":"Richards JR","year":"1999","journal-title":"West J Med"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0736-4679(98)00045-6"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-6723.2009.01182.x"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.3109\/15563650903333820"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1093\/qjmed\/hcm072"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.3109\/15563650.2015.1014044"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annemergmed.2014.12.005"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2011.107"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.5694\/mja14.01116"}],"container-title":["Drug and Alcohol Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fdar.12415","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fdar.12415","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/dar.12415","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T12:39:23Z","timestamp":1696336763000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/dar.12415"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5,30]]},"references-count":27,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,3]]}},"alternative-id":["10.1111\/dar.12415"],"URL":"https:\/\/doi.org\/10.1111\/dar.12415","archive":["Portico"],"relation":{},"ISSN":["0959-5236","1465-3362"],"issn-type":[{"value":"0959-5236","type":"print"},{"value":"1465-3362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,5,30]]},"assertion":[{"value":"2015-11-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-02-24","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-05-30","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}